Who is sponsoring NCT04409691?

NCT04409691 is sponsored by Shanghai Children's Medical Center.

What drugs are being tested in NCT04409691?

Interventions in NCT04409691: prednison and Sirolimus, prednison.

Is NCT04409691 still recruiting?

NCT04409691 is currently status unknown. Last updated 9 June 2020.

Last reviewed 2020-06-09 · How we verify

NCT04409691: SCMC-KK2020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SCMC Trial on KHE With KMP (V.2020)

Status unknown Phase 1 Last updated 9 June 2020

What this trial tests

Phase 1 trial testing prednison and Sirolimus in Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) in 20 participants. Status unknown.

Timeline

1 July 2020

Primary endpoint
31 January 2023

30 June 2023

Quick facts

Lead sponsor	Shanghai Children's Medical Center
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 July 2020
Primary completion	31 January 2023
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

prednison and Sirolimus — full drug profile →
prednison — full drug profile →

Conditions studied

Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) — all drugs for Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) →

Sponsor

Shanghai Children's Medical Center

Who can join

Under 12, any sex, with Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Children's Medical Center trials

Trials by the same sponsor.

NCT07383883 — Multimodal Tongue-Pulse Information Fusion for Syndrome Diagnosis and Cohort Study in Children With Asthma · recruiting
NCT07035821 — Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy · Phase 3 · not yet recruiting
NCT07003126 — A Cohort Study on Treating Primary Nocturnal Enuresis by Regulating Central-Peripheral Circadian Rhythm · NA · not yet recruiting
NCT07351955 — Clinical Study on a Novel Strategy of Individualized Non-Invasive Neuromodulation for the Treatment of Tic Disorders in · NA · recruiting
NCT07000656 — Micturition Desire-Relaxation Training Device for Lower Urinary Tract Dysfunction in Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04409691 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Children's Medical Center
Last refreshed: 9 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04409691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing